GSK plc Files 2016 Annual Report with U.S. Regulators
GSK plc has submitted its Form 20-F annual report for the fiscal year 2016 to the U.S. Securities and Exchange Commission. The filing details the company's financial status and operations.
Pharmaceutical company GSK plc has officially filed its Form 20-F annual report for the fiscal year ending December 31, 2016, with the U.S. Securities and Exchange Commission (SEC). The filing, dated March 17, 2017, serves as a comprehensive overview of the company's financial standing and operational activities for the preceding year.
The document outlines details regarding GSK's securities, including American Depositary Shares and various notes, listed on both the New York Stock Exchange and the London Stock Exchange. The company reported 5,368,316,062 ordinary shares of 25 pence par value outstanding as of the close of the reporting period.
GSK confirmed its status as a "large accelerated filer," indicating its significant market presence and reporting requirements in the United States. The financial statements within the report are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the IASB.
The Form 20-F is an annual report required by U.S. securities laws for foreign private issuers that have registered securities with the SEC. The filing incorporates information by reference from GSK's 2016 Annual Report.